[Clinical use of recombinant IFN alfa-2b in the treatment of primary cancer of the lung (preliminary results)].
In the period between January 1986 and December 1989 we have studied 60 patients with primitive lung cancer, subdivided in 3 groups according to the therapy: 20 were treated with surgery therapy, 20 with radiotherapy, 20 with chemotherapy. We have been studying a second group since September 1989; this is composed, until now, by 30 patients, subdivided in three groups as above. To each group we added alfa-2b recombinant Interferon at the dose of 3,000,000 i.m. three times a week for three months. We repeated the same therapy after three months. We have demonstrated that the combination alfa-2b recombinant interferon and the surgery therapy, radiotherapy and chemotherapy in patients with primitive lung cancer, can improve the quality of life but it doesn't prolong the duration of life.
Crispano
G
G
I Facoltà di Medicina e Chirurgia, Istituto di Clinica Tisiologica e Malattie Respiratorie Sergio Marcatili, Università degli Studi di Napoli Federico II.
Marzo
C
C
Calabrese
C
C
de Falco
A
A
D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Uso clinico dell'IFN alfa-2b ricombinante nel trattamento del cancro primitivo del polmone (risultati preliminari).